Stada Arzneimittel AG (SAZ) - Financial and Strategic SWOT Analysis Review

June 2019 | 55 pages | ID: SA14CA12848EN
GlobalData

Abstracts

Stada Arzneimittel AG (SAZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Stada Arzneimittel AG (STADA) is a manufacturer of low-cost generics and branded over the counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. It offers portfolio of products in various therapeutic categories including pain, women's health, cardiovascular conditions and diabetes. Few of its major generic products include including Tilidin Naloxon, Atorvastatin, Epoetin zeta and Diclofenac. Its major branded products include APO-Go, Grippostad, Snup, Fultium and Vitaprost. The company operates across Germany, Central Europe, CIS/Eastern Europe and Asia-Pacific. STADA is headquartered in Bad Vilbel, Germany.

Stada Arzneimittel AG Key Recent Developments

May 15,2019: STADA Health Report 2019: Half of Europeans are ready for Dr Robot and treatments via webcam
Mar 19,2019: STADA to hire hundreds of employees - Strong increase in earnings
Mar 19,2019: STADA with strong growth momentum in 2018
Oct 11,2018: STADA wins 2018 Global Generics & Biosimilars Award in Company of the Year, EMEA category
Sep 12,2018: STADA invites the holders of the STADA Bond to participate in the bondholders meeting and to vote in favor of the proposed resolutions

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Stada Arzneimittel AG - Key Facts
Stada Arzneimittel AG - Key Employees
Stada Arzneimittel AG - Key Employee Biographies
Stada Arzneimittel AG - Major Products and Services
Stada Arzneimittel AG - History
Stada Arzneimittel AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Stada Arzneimittel AG - Business Description
Product Category: Branded Products
Overview
Performance
Product Category: Generics
Overview
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Italy
Performance
Geographical Segment: Other Countries
Performance
Geographical Segment: Russia
Performance
Geographical Segment: Serbia
Performance
Geographical Segment: United Kingdom
Performance
R&D Overview
Stada Arzneimittel AG - Corporate Strategy
Stada Arzneimittel AG - SWOT Analysis
SWOT Analysis - Overview
Stada Arzneimittel AG - Strengths
Stada Arzneimittel AG - Weaknesses
Stada Arzneimittel AG - Opportunities
Stada Arzneimittel AG - Threats
Stada Arzneimittel AG - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Stada Arzneimittel AG, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 15, 2019: STADA Health Report 2019: Half of Europeans are ready for Dr Robot and treatments via webcam
Mar 19, 2019: STADA to hire hundreds of employees - Strong increase in earnings
Mar 19, 2019: STADA with strong growth momentum in 2018
Oct 11, 2018: STADA wins 2018 Global Generics & Biosimilars Award in Company of the Year, EMEA category
Sep 12, 2018: STADA invites the holders of the STADA Bond to participate in the bondholders meeting and to vote in favor of the proposed resolutions
Sep 03, 2018: Peter Goldschmidt to succeed Claudio Albrecht as STADA's CEO
Aug 09, 2018: STADA's business development in the first six months of 2018 as expected
May 03, 2018: STADA with solid business development in the first quarter of 2018
Apr 16, 2018: Changes in the management team of STADA
Mar 08, 2018: STADA records positive business development in 2017

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Stada Arzneimittel AG, Key Facts
Stada Arzneimittel AG, Key Employees
Stada Arzneimittel AG, Key Employee Biographies
Stada Arzneimittel AG, Major Products and Services
Stada Arzneimittel AG, History
Stada Arzneimittel AG, Subsidiaries
Stada Arzneimittel AG, Key Competitors
Stada Arzneimittel AG, Ratios based on current share price
Stada Arzneimittel AG, Annual Ratios
Stada Arzneimittel AG, Annual Ratios (Cont...1)
Stada Arzneimittel AG, Annual Ratios (Cont...2)
Stada Arzneimittel AG, Interim Ratios
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Stada Arzneimittel AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Stada Arzneimittel AG, Performance Chart (2013 - 2017)
Stada Arzneimittel AG, Ratio Charts
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Stada Arzneimittel AG, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Vifor Pharma Ltd
Turing Pharmaceuticals AG
MorphoSys AG
MediGene AG
HC Berlin Pharma AG
Evotec AG
EGIS Pharmaceuticals Plc
Biotest AG